Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations
Study sponsor: Kura Oncology, Inc. · KURA
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2020-12-14Actual
Enrollment · participants63Actual
Source updated2024-07-11Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.